Ginsenosides have been evaluated in diverse animal models of diabetic kidney disease, including high-fat diet (HFD) and streptozotocin (STZ)-induced rodent models and Db/Db mice with leptin receptor mutations, to assess their protective effects against diabetic kidney disease (Chen et al., 2023; Fan et al., 2023). Here, LEPR is linked to diabetic kidney disease.